Bryn Mawr Capital Management LLC Grows Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Bryn Mawr Capital Management LLC boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,678 shares of the company’s stock after purchasing an additional 80 shares during the quarter. Bryn Mawr Capital Management LLC’s holdings in IDEXX Laboratories were worth $5,927,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. Motley Fool Asset Management LLC increased its position in IDEXX Laboratories by 6.2% during the fourth quarter. Motley Fool Asset Management LLC now owns 2,565 shares of the company’s stock valued at $1,424,000 after acquiring an additional 150 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich increased its position in IDEXX Laboratories by 2.0% during the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 171,290 shares of the company’s stock valued at $95,074,000 after acquiring an additional 3,433 shares during the last quarter. Stevens Capital Management LP increased its position in IDEXX Laboratories by 22.3% during the fourth quarter. Stevens Capital Management LP now owns 1,570 shares of the company’s stock valued at $871,000 after acquiring an additional 286 shares during the last quarter. Syon Capital LLC bought a new position in IDEXX Laboratories during the fourth quarter valued at $397,000. Finally, Lyell Wealth Management LP increased its position in IDEXX Laboratories by 2.8% during the fourth quarter. Lyell Wealth Management LP now owns 19,980 shares of the company’s stock valued at $11,090,000 after acquiring an additional 550 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Piper Sandler cut shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective on the stock. in a research report on Tuesday, January 30th. Barclays boosted their price objective on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. JPMorgan Chase & Co. upped their price target on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Finally, The Goldman Sachs Group upped their price target on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $591.50.

IDEXX Laboratories Stock Up 2.1 %

Shares of IDEXX Laboratories stock opened at $499.30 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.57 and a quick ratio of 1.17. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The firm’s 50-day moving average is $531.02 and its two-hundred day moving average is $510.75. The stock has a market cap of $41.47 billion, a price-to-earnings ratio of 49.58, a PEG ratio of 3.77 and a beta of 1.26.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The company had revenue of $901.60 million for the quarter, compared to analysts’ expectations of $891.88 million. During the same period in the prior year, the business earned $2.05 EPS. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the completion of the sale, the chief executive officer now directly owns 79,247 shares of the company’s stock, valued at $45,377,624.67. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the completion of the sale, the chief executive officer now directly owns 79,247 shares of the company’s stock, valued at $45,377,624.67. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP George Fennell sold 8,198 shares of the stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the sale, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 43,524 shares of company stock valued at $24,871,960. 2.11% of the stock is currently owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.